FY2025 Earnings Estimate for ENSC Issued By Zacks Small Cap

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Equities research analysts at Zacks Small Cap decreased their FY2025 earnings estimates for Ensysce Biosciences in a research report issued on Monday, November 17th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will post earnings of ($4.73) per share for the year, down from their prior forecast of ($3.68). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share. Zacks Small Cap also issued estimates for Ensysce Biosciences’ Q4 2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.29) EPS.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings data on Friday, November 14th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.44). Ensysce Biosciences had a negative return on equity of 437.31% and a negative net margin of 244.47%.The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.70 million.

Several other research firms have also weighed in on ENSC. Wall Street Zen raised Ensysce Biosciences to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Ensysce Biosciences presently has a consensus rating of “Sell”.

Ensysce Biosciences Stock Down 1.5%

ENSC opened at $1.93 on Wednesday. The firm has a market capitalization of $6.83 million, a P/E ratio of -0.30 and a beta of 1.14. The stock has a fifty day moving average of $2.21 and a 200-day moving average of $2.19. Ensysce Biosciences has a 12-month low of $1.62 and a 12-month high of $11.13.

Institutional Investors Weigh In On Ensysce Biosciences

Institutional investors have recently made changes to their positions in the company. TRU Independence Asset Management 2 LLC bought a new stake in shares of Ensysce Biosciences in the 3rd quarter valued at approximately $25,000. Citadel Advisors LLC acquired a new stake in Ensysce Biosciences in the third quarter valued at approximately $34,000. Virtu Financial LLC bought a new stake in Ensysce Biosciences in the third quarter worth approximately $34,000. Adage Capital Partners GP L.L.C. increased its stake in shares of Ensysce Biosciences by 49.4% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 74,711 shares of the company’s stock worth $191,000 after purchasing an additional 24,711 shares during the last quarter. Finally, Murchinson Ltd. acquired a new position in shares of Ensysce Biosciences during the 1st quarter worth $358,000. 5.63% of the stock is currently owned by institutional investors and hedge funds.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.